Sustainability
Patients
Improving lives and efficient resource use with sustainable healthcare
With patients in focus, Camurus strives to reduce the impact of severe and chronic diseases, such as opioid dependence and rare diseases.
The goal is to be able to offer medicines with improved treatment outcomes, that provide an increased quality of life and a more efficient use of resources – thereby also contributing to a sustainable healthcare.
Material topics
Access to medicine
We aim to increase access to our products for as many people as possible. Camurus supports and collaborates with healthcare and patient organizations to reduce stigma and improve disease awareness – an important part of the work.
Product and patient safety
Product and patient safety is of highest priority, and Camurus follows and monitors marketed products for any product complaint and possible side effects. These are reported to health authorities in accordance with applicable laws and regulations.
Ethical clinical trials
Development of new medicines, both pre-clinical, e.g. animal testing, and clinical studies are conducted in accordance with applicable legislations, governing documents and quality system to steer for instance accurate and objective reporting, transparency, high ethics and patient integrity.
Read more about Camurus’ position on ethics in clinical trials
Our achievements
70,000
patientsestimated in treatment for opioid depence at the end of 2025*
* as at end December 2025
Access to medicines
Camurus aims to improve access to effective and convenient treatments for patients with severe and chronic diseases, such as opioid dependence and rare diseases. The goal is to increase access to treatments to potentially improve quality of life for as many people as possible.
Ethics in clinical trials
Camurus is determined to conduct clinical trials in an ethical manner. This includes protecting the safety, well-being and legal rights of all participants, and adhere to the highest ethical standards for clinical research.
In-depth data
For more in-depth data on focus area patients see Camurus' Annual Report 2025
References
- Buvidal (Europe, Australia, MENA) by 2027.